

1 Sex-based differences in clearance of chronic *Plasmodium*  
2 *falciparum* infection

3  
4 Jessica Briggs, M.D.<sup>1\*</sup>, Noam Teyssier, B.S.<sup>1</sup>, Joaniter I. Nankabirwa, Ph.D.<sup>2,3</sup>, John Rek, MSc<sup>2</sup>,  
5 Prasanna Jagannathan, M.D.<sup>4</sup>, Emmanuel Arinatiwe, MPH<sup>2,9</sup>, Teun Bousema, Ph.D.<sup>5,6</sup>, Chris  
6 Drakeley, Ph.D.<sup>6</sup>, Margaret Murray, M.S.<sup>4</sup>, Emily Crawford, Ph.D.<sup>7</sup>, Nicholas Hathaway, M.D.<sup>8</sup>,  
7 Sarah G. Staedke, Ph.D.<sup>9</sup>, David Smith, Ph.D.<sup>10</sup>, Phillip J. Rosenthal, M.D.<sup>1</sup>, Moses Kanya,  
8 Ph.D.<sup>2,3</sup>, Grant Dorsey, M.D.<sup>1</sup>, Isabel Rodriguez-Barraquer, M.D.<sup>1\*\*</sup>,  
9 Bryan Greenhouse, M.D.<sup>1\*\*</sup>

10 **\*\*co-senior authors**

11  
12 <sup>1</sup> Department of Medicine, University of California San Francisco, San Francisco, CA  
13 <sup>2</sup> Infectious Diseases Research Collaboration, Kampala, Uganda  
14 <sup>3</sup> Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda  
15 <sup>4</sup> Department of Medicine, Stanford University, Palo Alto, CA  
16 <sup>5</sup> Department of Medical Microbiology, Radboud University Nijmegen Medical Centre,  
17 Nijmegen, the Netherlands  
18 <sup>6</sup> Department of Immunology and Infection, London School of Hygiene and Tropical Medicine,  
19 London, UK  
20 <sup>7</sup> Chan-Zuckerberg Biohub, San Francisco, CA  
21 <sup>8</sup> Department of Medicine, University of Massachusetts, Amherst, MA  
22 <sup>9</sup> Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK  
23 <sup>10</sup> Institute for Health Metrics & Evaluation, University of Washington, Seattle, WA

24  
25  
26  
27

28 **\*Corresponding Author:** Jessica Briggs, Rm 525 Building 3, Zuckerberg San Francisco  
29 General Hospital, San Francisco, CA. Email: [jessica.briggs@ucsf.edu](mailto:jessica.briggs@ucsf.edu)

30  
31  
32

33

34  
35  
36  
37

38 **Key words:** malaria, asymptomatic infection, force of infection, duration of infection,  
39 genotyping, sex-based differences

40 **Abstract**

41

42 Multiple studies have reported a male bias in incidence and/or prevalence of malaria infection in  
43 males compared to females. To test the hypothesis that sex-based differences in host-parasite  
44 interactions affect the epidemiology of malaria, we intensively followed *Plasmodium falciparum*  
45 infections in a cohort in a malaria endemic area of eastern Uganda and estimated both force of  
46 infection (FOI) and rate of clearance using amplicon deep-sequencing. We found no evidence of  
47 differences in behavioral risk factors, incidence of malaria, or FOI by sex. In contrast, females  
48 cleared asymptomatic infections at a faster rate than males (hazard ratio [HR] = 1.82, 95% CI  
49 1.20 to 2.75 by clone and HR = 2.07, 95% CI 1.24 to 3.47 by infection event) in multivariate  
50 models adjusted for age, timing of infection onset, and parasite density. These findings implicate  
51 biological sex-based differences as an important factor in the host response to this globally  
52 important pathogen.

53

54

55

56

57

58

59

60

## 61 Introduction

62 Malaria, a protozoan infection of the red blood cells, remains one of the greatest global  
63 health challenges<sup>1</sup>. Infection with malaria parasites results in a wide range of clinical disease  
64 presentations, from severe to uncomplicated; in addition, in hyperendemic areas, asymptomatic  
65 infections are common<sup>2</sup>. It is well established that chronic asymptomatic infection with  
66 *Plasmodium falciparum*, the most common and fatal malaria parasite, can lead to morbidity for  
67 those infected and contribute to ongoing transmission<sup>2-5</sup>. Characterization of these  
68 asymptomatic infections is paramount as they represent a major obstacle for malaria elimination  
69 efforts. Therefore, an understanding of how host immunity and parasite factors interact to cause  
70 disease tolerance is required. While age-specific immunity to malaria in hyperendemic areas is  
71 well-characterized, less attention has been paid to the possibility of a sex bias in malarial  
72 susceptibility despite evidence for a male bias in malaria infections in non-human animals and a  
73 male bias in the prevalence of other human parasitic infections<sup>6-8</sup>.

74 The clearest evidence for sexual dimorphism in malaria susceptibility is in pregnant  
75 women, who are at greater risk of malaria infection and also experience more severe disease  
76 and higher mortality<sup>9</sup>. However, multiple studies performed in different contexts have  
77 demonstrated a male bias in incidence and/or prevalence of malaria infection in school aged  
78 children and adults;<sup>10-14</sup> this bias is more well established in hypoendemic areas, but has also  
79 been observed in hyperendemic regions.<sup>15,16</sup> It has often been postulated that these differences  
80 in malaria incidence or prevalence stem from an increased risk of males acquiring infection due  
81 to socio-behavioral factors<sup>11,13,17,18</sup>. However, biological sex itself has been demonstrated to  
82 affect responses to other pathogens, and thus an alternative hypothesis is that the sexes have  
83 different responses to the malaria parasite once infected<sup>19-22</sup>.

84

85 Estimating the host response to *P. falciparum* infection requires close follow up of  
86 infected individuals, sensitive detection of parasites, and the ability to distinguish superinfection,  
87 which is common in endemic areas, from persistent infection. To test the hypothesis that sex-  
88 based differences in host-parasite interactions affect the epidemiology of malaria, we intensively  
89 followed a representative cohort of individuals living in a malaria endemic area of eastern  
90 Uganda. Using frequent sampling, ultrasensitive quantitative PCR (qPCR), and amplicon deep  
91 sequencing to genotype parasite clones, we were able to accurately detect the onset of new  
92 infections and follow all infections over time to estimate their duration. Using these data, we  
93 show that females cleared their asymptomatic infections more rapidly than males, implicating  
94 biological sex-based differences as important in the host response to this globally important  
95 pathogen.

## 96 **Results**

97

### 98 **Cohort participants and *P. falciparum* infections**

99 This analysis involved data from 477 children and adults (233 males and 244 females)  
100 that were followed for a total of 669.6 person-years (Table 1). 25 participants, 10 males and 15  
101 females, were enrolled after initial enrollment (Figure 1); median duration of follow up in those  
102 who were dynamically enrolled was 0.84 years (IQR 0.69-1.23) compared to 1.45 years (IQR  
103 1.43-1.47) in those enrolled during initial enrollment. 149 of 477 participants (31.2%) included in  
104 the analysis had at least one *P. falciparum* infection detected (Figure 1). 114 participants had  
105 822 successfully genotyped samples and had infections characterized by clone and by infection  
106 event. We achieved a read count of >10,000 for 92% of genotyped samples, identifying 45  
107 unique AMA-1 clones in our population (frequencies and sequences in **Supplemental File 1e**).  
108 35 samples had very low-density infections (< 1 parasite/ $\mu$ L) that could not be genotyped and  
109 had infections characterized at the event level only. There were more baseline infections in

110 males at the clone level, with 117/185 (63.2%) baseline infections in males and 68/185 (36.8%)  
111 baseline infections in females ( $p < 0.001$ ). At the infection event level, there was no difference in  
112 the number of baseline infections by sex, with 54/99 (54.4%) baseline infections in males and  
113 45/99 (45.5%) baseline infections in females and ( $p = 0.26$ ).

114

## 115 **Behavioral malaria risk factors and measures of malaria burden**

116 There was no difference in reported rates of LLIN use the previous night by sex (Table  
117 1). Women over the age of 16 traveled overnight outside of the study area more than men  
118 (incidence rate ratio [IRR] for females vs. males = 3.61, 95% confidence interval [CI] 1.83 to  
119 7.13), a potential risk factor for malaria exposure. Antimalarial use outside the study clinic was  
120 reported only 4 times (3 females and 1 male, all under the age of 5). In this region receiving  
121 regular rounds of IRS, the incidence of symptomatic malaria was low in all age categories, and  
122 there was no evidence of a difference in incidence of symptomatic malaria by sex overall (IRR  
123 for females vs. males = 1.11, 95% CI 0.49 to 2.52) or when adjusted for age (IRR = 1.26, 95%  
124 CI 0.54 to 2.96). In contrast, prevalence ratio (PR) of *P. falciparum* parasitemia by microscopy in  
125 females versus males across all age categories was 0.49 (95% CI 0.36 to 0.65), with relative  
126 differences in prevalence most pronounced in the oldest age group. Similar findings were seen  
127 when prevalence was assessed by ultrasensitive qPCR, with PR = 0.64 in females vs. males  
128 (95% CI 0.43 to 0.96), again with the largest differences seen in the oldest age group. Adjusting  
129 for age as a categorical variable, LLIN use, and travel did not qualitatively change prevalence  
130 ratios for microscopic parasitemia (PR in females vs. males = 0.57, 95% CI 0.42 to 0.77) or for  
131 qPCR-positive parasitemia (PR in females vs. males = 0.67, 95% CI 0.60 to 0.76). We also  
132 found no evidence for a difference in parasite density as determined by qPCR between males  
133 and females after adjusting for age as a continuous variable ( $p = 0.47$ ). Median COI was higher  
134 in males than in females overall, driven primarily by a higher COI in male school aged children.

135

136 **Force of infection by age and sex**

137 To determine whether higher infection prevalence in males was due to an increased rate  
138 of infection, we used longitudinal genotyping to calculate the force of infection (FOI, number of  
139 new blood stage infections per unit time). Overall, the FOI was low, with new infections  
140 occurring on average less than once every 5 years (Table 2). There was no evidence for a  
141 significant difference in FOI by sex overall (IRR for females vs. males = 0.88, 95% CI 0.48 to  
142 1.62 by clone and IRR = 0.83, 95% CI 0.52 to 1.33 by infection event). There was also no  
143 evidence for a significant difference in FOI by sex when adjusted for age category (IRR = 0.88,  
144 95% CI 0.47 to 1.63 by clone and IRR = 0.83, 95% CI 0.53 to 1.31 by infection event). For  
145 analysis both by clone and by infection event, there was a trend toward higher FOI in males  
146 compared to females. We performed a sensitivity analysis by decreasing the number of skips  
147 necessary to declare an infection cleared (Supplemental File 1f). Performing the same analysis  
148 using 1 skip for clearance instead of 3 skips increased the FOI in all groups and increased the  
149 trend toward higher FOI in males, with IRR for females vs. males when adjusted for age  
150 category = 0.71, 95% CI 0.41 to 1.24 by clone and IRR = 0.75, 95% CI 0.47 to 1.22 by infection  
151 event.

152

153 **Rate of clearance of infection and duration of infection by sex**

154 Since females had a lower prevalence of infection but similar rate of acquiring infections  
155 compared to males, we evaluated whether there was a difference between sexes in the rate at  
156 which infections were cleared. Asymptomatic infections were included in this analysis if they  
157 were not censored as stated in the methods; at the clone level, 105 baseline infections and 53  
158 new infections were included. At the infection event level, 58 baseline infections and 51 new  
159 infections were included. There were more baseline infections in males at the clone level, with  
160 68/105 (64.8%) baseline infections in males and 37/105 (35.2%) baseline infections in females  
161 ( $p < 0.001$ ). At the infection event level, there was no difference in the number of baseline

162 infections by sex, with 32/58 (55.2%) baseline infections in males and 26/58 (44.8%) baseline  
163 infections in females ( $p = 0.35$ ).

164 Unadjusted hazard ratios for clearing infecting clones showed that asymptomatic  
165 infections cleared naturally (*i.e.*, when not treated by antimalarials) at nearly twice the rate in  
166 females vs. males (hazard ratio (HR) 1.92, 95% CI 1.19 to 3.11, Table 3). In addition, new  
167 infections cleared faster than baseline infections and monoclonal infections cleared faster than  
168 polyclonal infections. Unadjusted hazard ratios for clearance of infection events (as opposed to  
169 clones) also showed faster clearance in females vs. males (HR = 2.30, 95% CI 1.20 to 4.42).  
170 Results were similar in multivariate models including age, gender, the period during which the  
171 infection was first observed, and parasite density, demonstrating faster clearance in females vs.  
172 males (HR =1.82, 95% CI 1.20 to 2.75 by clone and HR =2.07, 95% CI 1.24 to 3.47 by infection  
173 event). Complexity of infection was not included in the final adjusted model because the model  
174 fit the data less well when COI was included as a predictor. In both adjusted models, new  
175 infections cleared faster than baseline infections. Higher parasite densities were associated with  
176 slower clearance by clone and by infection event, but the effect size was larger when data were  
177 analyzed by infection event (HR = 0.44, 95% CI 0.35 to 0.54). There was no evidence for  
178 interaction between age and sex in either adjusted model. We performed a sensitivity analysis  
179 by decreasing the number of skips necessary to declare an infection cleared. Regardless of  
180 whether 3 skips, 2 skips, or 1 skip was used to determine infection clearance, females cleared  
181 their infections faster than males both by clone and by infection event (Supplemental File 1g).

182 We next estimated durations of asymptomatic infection by age and sex using results  
183 from a model that included these covariates (Figure 2). Durations of infection ranged from 103  
184 days to 447 days by clone, and from 87 to 536 days by infection event. Males had a longer  
185 duration of infection across all age categories. Children aged 5-15 years had the longest  
186 duration of infection, followed by adults. Therefore, overall, males aged 5-15 years had the  
187 longest estimated duration of infection by either clone (447 days) or infection event (526 days).

188

## 189 Discussion

190 Previous studies have reported a higher prevalence of malaria infection in males  
191 compared to females, with the difference often ascribed to differences in exposure<sup>10-16</sup>. In a  
192 cohort study in eastern Uganda, we noted higher prevalence of malaria infection in males  
193 compared to females. By closely following a cohort of children and adults and genotyping every  
194 detected infection with sensitive amplicon deep-sequencing, we were able to estimate both the  
195 rate of infection (FOI) and duration of infection and to compare these measures by sex. We  
196 found that lower prevalence in females did not appear to be due to lower rates of infection but  
197 rather due to faster clearance of asymptomatic infections. To our knowledge, this is the first  
198 study to report a sex-based difference in the duration of malaria infection.

199 Many prior studies of malaria incidence and/or prevalence that evaluated associations  
200 with sex in late childhood, adolescence and adulthood have found a male bias in the observed  
201 measure of burden<sup>10-16</sup>. Overall, these studies consistently suggest that males exhibit higher  
202 incidence and/or prevalence of malaria that begins during late childhood, persisting through  
203 puberty and the majority of adulthood (excepting the years when pregnancy puts women at  
204 higher risk). One possible explanation put forward for the sex-specific difference in burden has  
205 been that males are more frequently bitten by malaria-carrying mosquitos due to behavioral  
206 differences such as working outside, not sleeping under a net, or traveling for work<sup>11,13,17,18</sup>. In  
207 our study, however, there were no statistically significant differences in malaria incidence or FOI  
208 by sex, though there was a trend toward higher FOI in males. We also saw no evidence of  
209 behavioral trends that would result in more infections in males; in fact, older women in our study  
210 did most of the traveling outside the study area (an area of low transmission compared to  
211 surrounding areas). We did not assess work habits as part of our study questionnaire, but the  
212 fact that we observe similar patterns in prevalence by sex in all age categories makes this a less



213 likely explanation. Therefore, in this particular cohort, it appears that the observed male bias in  
214 parasite prevalence is best explained by slower clearance of infection in males. We cannot rule  
215 out that males were differentially exposed in the recent past (e.g., had a higher force of infection  
216 when transmission was higher, which could have affected immunity), and we plan to genotype  
217 samples from a prior cohort from 2011-2017 to test this hypothesis.

218         Very few studies have been conducted to explore immunological differences between  
219 males and females in their response to the malaria parasite. RTS,S vaccination is associated  
220 with higher all-cause mortality in girls compared to boys, and a trend toward higher risk of fatal  
221 malaria has been noted in vaccinated girls compared to boys, suggesting possible sexual  
222 dimorphism in immunological responses to malaria<sup>23</sup>. The comprehensive Garki project found  
223 that females had higher levels of antibodies against *P. falciparum* compared to men<sup>10</sup>. Hormonal  
224 differences have been posited to play a role in these sex-based immunological differences to  
225 malaria infection; studies in mice show that testosterone appears to downregulate the immune  
226 response to malaria<sup>24,25</sup>. If sex-based differences were purely hormonally mediated, one might  
227 expect a stronger effect in adults than in school-aged children, which was not seen in this  
228 cohort. This could be due to imperfect detectability, as adults have lower density infections than  
229 school-aged children due to improved anti-parasite immunity<sup>2,3</sup>. Post-menopausal women were  
230 also included in the oldest age group, which could have blunted the effect of sex in that age  
231 group if there is a hormonal basis for some of this effect. It is also possible that sex-based  
232 differences are explained by a different mechanism, such as differences in innate immunity.  
233 More studies are needed to elucidate the relationship between sex-based biological differences  
234 between males and females and their impact on the development of effective antimalarial  
235 immunity in humans.

236         Of the variables we evaluated in addition to sex, baseline infection status and parasite  
237 density were most strongly associated with the rate of clearance of infection. Infections that  
238 were already present at the beginning of the study and persisted past the left censoring date

239 may have been a non-random selection of well-established asymptomatic infections that were  
240 present at baseline at a higher frequency than average because they had a fundamentally  
241 different trajectory than newly established asymptomatic infections. Higher parasite densities  
242 were also associated with slower clearance of infection in both adjusted models, but the effect  
243 was most pronounced when the data were analyzed by infection event. This may be because  
244 low-density infections that we were unable to successfully genotype were only included in the  
245 infection event analysis, and these events tended to have short durations. The inclusion of  
246 parasite density in our multivariate models did not meaningfully alter associations between sex  
247 and duration of infection, providing evidence that the sex-based differences in duration were not  
248 mediated primarily by differences in parasite density in our cohort.

249 A limitation of our study is the statistical model's assumption that all infections clear at  
250 the same rate, which was necessary because we did not observe the beginning of most  
251 infections. To rely less on this assumption, we adjusted for baseline infections, allowing them to  
252 have a different rate of clearance than new infections; this did not change our primary finding of  
253 a difference in rate of clearance by sex. We also acknowledge there may be other unmeasured  
254 confounders, such as genetic hemoglobinopathies or sex-based differences in unreported  
255 outside antimalarial use, that could affect our results. Another caveat is that our findings may  
256 not be generalizable to areas with different transmission intensity given that our study was  
257 conducted in a unique area with previously very high transmission intensity that has been  
258 greatly reduced in recent years by repeated rounds of IRS.

259 Additionally, because it is difficult to genotype low density infections and because  
260 parasite densities fluctuate over time, we allowed several "skips" in detection before declaring  
261 an infection cleared or the same clone in an individual a new infection with the same clone. This  
262 requires the assumption that re-infection with the same clone is relatively rare, which is  
263 reasonable given the high genetic diversity and low force of infection seen in this setting; this

264 assumption has been made in other longitudinal genotyping studies<sup>26,27</sup>. Our method may have  
265 biased us toward longer durations of infection and fewer new infections overall, but this is  
266 unlikely to have introduced any significant bias in the observed associations by sex. We  
267 performed a sensitivity analysis to ensure that changing the number of skips allowed did not  
268 significantly change the main finding regarding longer duration of infection in males and our  
269 findings were consistent. Given decreasing parasite densities over time and a setting with low  
270 force of infection and low EIR, assuming perfect recovery of clones is likely to artificially inflate  
271 the force of infection in this cohort.

272 In summary, we estimated the clearance of asymptomatic *P. falciparum* infections by  
273 genotyping longitudinal samples from a cohort in Nagongera, Uganda, using sensitive amplicon  
274 deep-sequencing and found that females cleared their infections at a faster rate than males; this  
275 finding remained consistent when adjusting for age, baseline infection status, and parasite  
276 density. Furthermore, we found no conclusive evidence for a sex-based difference in exposure  
277 to infection, either behaviorally or by FOI. Though there have long been observed differences in  
278 malaria burden between the sexes, there is still little known about sex-based biological  
279 differences that may mediate immunity to malaria. Unfortunately, much reported malaria data is  
280 still sex-disaggregated. Our findings should encourage epidemiologists to better characterize  
281 sexual dimorphism in malaria and motivate increased research into biological explanations for  
282 sex-based differences in the host response to the malaria parasite.

## 283 **Materials and Methods**

### 284 **Study setting and population-level malaria control interventions**

285 This cohort study was carried out in Nagongera sub-county, Tororo district, eastern  
286 Uganda, an area with historically high malaria transmission. However, 7 rounds of indoor  
287 residual spraying (IRS) from 2014-2019 have resulted in a significant decline in the burden of

288 malaria<sup>28</sup>. Pre-IRS, the daily human biting rate (HBR) was 34.3 and the annual entomological  
289 inoculation rate (EIR) was 238; after 5 years of IRS, in 2019 the daily HBR was 2.07 and overall  
290 annual EIR was 0.43 as reported by Nankabirwa et. al.<sup>29</sup>

291

## 292 **Study design, enrollment, and follow-up**

293 All members of 80 randomly selected households with at least two children were  
294 enrolled in October 2017 using a list generated by enumerating and mapping all households in  
295 Nagongera sub-county<sup>29</sup>. The cohort was dynamic such that residents joining the household  
296 were enrolled and residents leaving the household were withdrawn. Data for this analysis was  
297 collected from October 1<sup>st</sup>, 2017 through March 31<sup>st</sup>, 2019; participants were included if they  
298 had at least 6 months of contiguous follow up. Participants were followed at a designated study  
299 clinic open daily from 8 AM to 5 PM. Participants were encouraged to seek all medical care at  
300 the study clinic and avoid the use of antimalarial medications outside of the study. Routine visits  
301 were conducted every 28 days and included a standardized clinical evaluation, assessment of  
302 overnight travel outside of Nagongera sub-county, and collection of blood by phlebotomy for  
303 detection of malaria parasites by microscopy and molecular studies. Participants came in for  
304 non-routine visits in the setting of illness. Blood smears were performed at enrollment, at all  
305 routine visits and at non-routine visits if the participant presented with fever or history of fever in  
306 the previous 24 hours. Participants with fever (>38.0°C tympanic) or history of fever in the  
307 previous 24 hours had a thick blood smear read urgently. If the smear was positive, the patient  
308 was diagnosed with malaria and treated with artemether-lumefantrine. Participants with  
309 asymptomatic parasitemia as detected by qPCR or microscopy were not treated with  
310 antimalarials, consistent with Uganda national guidelines. Study participants were visited at  
311 home every 2 weeks to assess use of long-lasting insecticidal nets (LLINs) the previous night.

312

## 313 **Laboratory methods**

314           Thick blood smears were stained with 2% Giemsa for 30 minutes and evaluated for the  
315 presence of asexual parasites and gametocytes. Parasite densities were calculated by counting  
316 the number of asexual parasites per 200 leukocytes (or per 500, if the count was less than 10  
317 parasites per 200 leukocytes), assuming a leukocyte count of 8,000/ $\mu$ L. A thick blood smear was  
318 considered negative if examination of 100 high power fields revealed no asexual parasites. For  
319 quality control, all slides were read by a second microscopist, and a third reviewer settled any  
320 discrepant readings. In our experienced microscopists' hands, the lower limit of detection is  
321 approximately 20-50 parasites/ $\mu$ L.

322           For qPCR and genotyping, we collected 200  $\mu$ L of blood at enrollment, at each routine  
323 visit, and at the time of malaria diagnosis. DNA was extracted using the PureLink Genomic DNA  
324 Mini Kit (Invitrogen) and parasitemia was quantified using an ultrasensitive varATS qPCR assay  
325 with a lower limit of detection of 0.05 parasites/ $\mu$ L<sup>30</sup>. Samples with a parasite density  $\geq$  0.1  
326 parasites/ $\mu$ L blood were genotyped via amplicon deep-sequencing. All samples positive for  
327 asexual parasites by microscopy but negative for *P. falciparum* by qPCR were tested for the  
328 presence of non-falciparum species using nested PCR.<sup>31</sup>

329

### 330 *Sequencing library preparation*

331           Hemi-nested PCR was used to amplify a 236 base-pair segment of apical membrane  
332 antigen 1 (AMA-1) using a published protocol<sup>32</sup>, with modifications (**Supplemental File 1a**).

333 Samples were amplified in duplicate, indexed, pooled, and purified by bead cleaning.

334 Sequencing was performed on an Illumina MiSeq platform (250bp paired-end).

335

## 336 **Bioinformatics methods**

337 Data extraction, processing, and haplotype clustering were performed using SeekDeep<sup>33</sup>,

338 followed by additional filtering<sup>34</sup>. **Supplemental File 1b** shows the full bioinformatics workflow.

339

## 340 **Data analysis**

341           A clone was defined as a genetically identical group of parasites, e.g., with identical  
342 haplotypes. Because polyclonal infections can occur due to co-infection (one mosquito bite  
343 transmitting multiple clones) or superinfection (multiple bites), we analyzed the infection data  
344 both by clone and by infection event. For analysis by clone, each unique clone was counted as  
345 an infection and each clone's disappearance as a clearance event. For analysis by infection  
346 event, any new clones seen within 3 visits of the date of the first newly detected clone(s) were  
347 grouped together and considered one new "infection event." Clearance of infection for these  
348 events required that all clones in the group be absent. A baseline infection was defined as a  
349 clone or infection event (group of clones) detected in the first 60 days of observation. New  
350 infections were defined as a new clone or infection event (group of clones) detected in an  
351 individual after day 60.

352           Imperfect detection of *P. falciparum* clones is known to be a limitation of all PCR-based  
353 genotyping methods; both biological factors, such as deep organ sequestration of clones in the  
354 lifecycle of the parasite, and methodological factors, such as difficulty amplifying minority clones  
355 (especially at lower parasite densities), results in imperfect detectability of all clones present in a  
356 single blood sample drawn on a single day.<sup>26,35–38</sup> Though amplicon deep sequencing is less  
357 likely than other methods to miss minority clones<sup>39</sup>, detectability was a particular concern in our  
358 study, in which the majority of infections were submicroscopic and parasite densities declined  
359 over time [Supplemental File 1c]. To account for the fact that a clone might be missed in a  
360 single sample due to fluctuations in parasite density and/or methodological limitations, we  
361 allowed 3 "skips" in detection and classified an infection as cleared only if it was not identified in  
362 4 contiguous samples from routine visits. If the infection (as determined by clone or by infection  
363 event) was absent for 4 routine samples in a row, the last date of detection would be the end  
364 date of that infection. Therefore, for a clone that had previously infected an individual to be

365 classified as a new infection, it had to have been absent from that individual for at least 4 routine  
366 visits. Additional details are found in **Supplemental File 1d**. This decision was supported by the  
367 fact that the diversity of the genotyped AMA-1 amplicon was quite high (expected  
368 heterozygosity = 0.949), resulting in a low probability (5.1%) for infection with the same clone by  
369 chance.

370 Data analysis was conducted in R<sup>40</sup> and Python<sup>41</sup>. Microscopic parasite prevalence was  
371 defined by the number of smear-positive routine visits over all routine visits. Parasite prevalence  
372 by qPCR was defined as the number of qPCR-positive visits over all routine visits. Prevalence  
373 ratios were computed using Poisson regression with generalized estimating equations to adjust  
374 for repeated measures. Comparison of parasite density by sex was made using linear  
375 regression with generalized estimating equations to adjust for repeated measures. Force of  
376 infection (FOI) was defined as the number of new infections, including malaria episodes, divided  
377 by person time. Poisson regression with generalized estimating equations to account for  
378 repeated measures was used to estimate malaria incidence, FOI, and to calculate incident rate  
379 ratios (IRR) for malaria and FOI. Hazards for clearance of untreated, asymptomatic infections  
380 were estimated using time-to-event models (shared frailty models fit using R package  
381 “frailtypack,” version 2.12.2)<sup>42,43</sup>. Infections were censored if they were only observed in the first  
382 three months or the last three months (before January 01, 2018 and after January 01, 2019)  
383 because they were not observed for long enough to determine whether clearance occurred. If  
384 an infection was observed for only one timepoint, it was assigned a duration of 14 days. These  
385 models assumed a constant hazard of clearance and included random effects to account for  
386 repeated measures in individuals. Parasite density was included in the model as a time-varying  
387 covariate. Duration of infection in days was calculated as 1/adjusted hazard.

#### 388 **Data Accessibility**

389           Data from the cohort study is available through an open-access clinical epidemiology  
390 database resource, ClinEpiDB at [https://clinepidb.org/ce/app/record/dataset/DS\\_51b40fe2e2](https://clinepidb.org/ce/app/record/dataset/DS_51b40fe2e2).  
391 Genotyping data and code used to generate tables and figures is available on GitHub<sup>44</sup>.

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412


413

414



415 **Figure Legends**

416 **Figure 1. Study design.**



417

418

419

420

421

422

423


424

425

426

427 **Figure 2. Estimates of duration of infection from sex- and age-adjusted model**

428



429

430 Estimated duration of infection in days, calculated by adjusting the point estimate of the baseline  
431 hazard by the coefficients of the sex- and age-adjusted model. Error bars represent standard  
432 errors of duration obtained from variance in the model coefficients. Point estimates of duration  
433 are labeled (\*).

434

435

436

437

438

439 **Supplemental File Legends**

440

441 **Supplemental File 1a. AMA-1 hemi-nested PCR protocol for amplicon deep-sequencing**

442 **Supplemental File 1b: Bioinformatics workflow**

443 **Supplemental File 1c. Declining qPCR density over time in the cohort.**

444 **Supplemental File 1d. Detailed explanation of skip rule criteria**

445 **Supplemental File 1e. Haplotype sequences and frequencies**

446 **Supplemental File 1f. Sensitivity analysis of molecular force of infection: Table 2**

447 **replicated using 2 skips or 1 skip**

448 **Supplemental File 1g. Sensitivity analysis of duration of infection: Table 3 replicated**

449 **using 2 skips or 1 skip**

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466 **Table 1. Behavioral risk factors for malaria infection and measures of malaria burden in study population, stratified by age and sex**  
 467

Metric	Age and gender categories							
	All		< 5 years old		5-15 years old		16 years and older	
	Male	Female	Male	Female	Male	Female	Male	Female
Number of participants, n	233	244	73	84	101	71	59	89
Median days of follow-up per participant	530.0	530.0	525.0	524.5	530.0	531.0	530.0	530.0
Left under LLIN the previous night	53.6%	56.3%	54.1%	56.3%	47.9%	47.8%	63.7%	64.3%
Person-years of follow up	324.2	345.4	87.3	96.7	152.6	118.5	84.22	130.1
Number of overnight trips	44	107	21	19	9	10	14	78
Incidence of overnight trips*, (95% CI)	0.14 (0.09-0.20)	0.31 (0.20-0.49)	0.24 (0.14-0.42)	0.20 (0.09-0.42)	0.06 (0.03-0.13)	0.08 (0.03-0.24)	0.17 (0.09-0.31)	0.60 (0.30-1.18)
Episodes of malaria**, (incidence*)	11	13	5	2	5	9	1	2
Incidence of malaria*, (95% CI)	0.03 (0.02-0.06)	0.04 (0.02-0.09)	0.06 (0.02—0.16)	0.02 (0.00-0.11)	0.03 (0.01-0.08)	0.08 (0.03-0.23)	0.01 (0.00-0.08)	0.02 (0.00-0.17)
Number of routine visits, n	4,316	4,583	1164	1293	2034	1568	1118	1722
Prevalence of microscopic parasitemia***	2.9%	1.4%	1.8%	1.1%	4.4%	2.7%	1.3%	0.5%
Prevalence of parasitemia by qPCR	14.4%	9.2%	5.8%	3.7%	17.0%	15.3%	18.5%	7.7%
Geometric mean parasite density****	3.41	3.06	4.86	13.06	6.31	4.20	1.09	1.02
Median complexity of infection, (IQR)	3 (1-7)	2 (1-2)	1 (1-2.5)	2 (1-2.3)	4 (2-9)	2 (1-2)	1 (1-2)	1 (1-2)

468 \*per person-year

469 \*\*Malaria includes 1 episode (female, < 5 years old), due to non-falciparum species (*P. malariae*)

470 \*\*\*Parasitemia by light microscopy includes 1 episode (female, 5-15 years old) due to non-falciparum species (*P. ovale*)

471 \*\*\*\*Geometric mean parasite density in parasites/μL of all qPCR-positive routine visits

472 **Table 2. Molecular force of infection (FOI) by clone and by infection event, stratified by age and sex**

473

Molecular force of infection (FOI)	Sex	Age category			
		All	< 5 years	5-15 years	16 years or older
By clone, ppy* (95% CI)	All	0.18 (0.13-0.24)	0.14 (0.07-0.28)	0.19 (0.08-0.43)	0.20 (0.08-0.46)
	Male	0.19 (0.12-0.30)	0.16 (0.07-0.39)	0.19 (0.10-0.37)	0.22 (0.09-0.54)
	Female	0.17 (0.09-0.31)	0.12 (0.03-0.49)	0.19 (0.08-0.45)	0.18 (0.06-0.54)
By event, ppy* (95% CI)	All	0.14 (0.11-0.18)	0.09 (0.06-0.16)	0.16 (0.09-0.30)	0.16 (0.08-0.32)
	Male	0.16 (0.11-0.22)	0.13 (0.07-0.27)	0.18 (0.11-0.28)	0.15 (0.07-0.29)
	Female	0.13 (0.08-0.21)	0.06 (0.02-0.18)	0.14 (0.07-0.27)	0.17 (0.07-0.41)

474 \*per person-year

475 **Table 3. Hazard ratios for rates of clearance of infection, by clone and by infection event**

476

Predictors	Categories	Hazard ratio by clone (95% CI)		Hazard ratio by infection event (95% CI)	
		Unadjusted	Adjusted	Unadjusted	Adjusted
Sex	Male	ref	ref	ref	ref
	Female	1.92 (1.19-3.11)	1.82 (1.20 – 2.75)	2.30 (1.20 – 4.42)	2.07 (1.24 – 3.47)
Age	16 years or greater	ref	ref	ref	ref
	5-15 years	0.66 (0.39 – 1.10)	0.81 (0.49 – 1.36)	0.82 (0.39 – 1.74)	1.27 (0.72 – 2.25)
	< 5 years	1.64 (0.79 – 3.41)	1.55 (0.76 – 3.17)	2.01 (0.80 – 5.00)	1.75 (0.87 – 3.53)
Complexity of infection (COI)	Polyclonal (COI > 1)	ref	--	ref	--
	Monoclonal (COI = 1)	1.63 (1.03 – 2.57)	--	0.95 (0.38 – 2.34)	--
Infection status	Present at baseline	ref	ref	ref	ref
	New infection	1.94 (1.22 – 3.07)	1.75 (1.05 – 2.94)	4.66 (2.58 – 8.42)	4.32 (2.59 – 7.20)
Parasite density *		0.85 (0.69 – 1.06)	0.81 (0.65 – 1.00)	0.41 (0.32 – 0.51)	0.44 (0.35 – 0.54)

477 \*Increasing parasite density (log10) in parasites/microliter, as measured by qPCR

478

479

480

481

482

483

484

485 **REFERENCES**

486

- 487 1. World malaria report 2019 [Internet]. [cited 2020 Aug 5]. Available from:  
488 <https://www.who.int/publications-detail-redirect/9789241565721>
- 489 2. Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: detectability,  
490 transmissibility and public health relevance. *Nat Rev Microbiol*. 2014;12(12):833–840.  
491 PMID: 25329408
- 492 3. Okell LC, Bousema T, Griffin JT, Ouedraogo AL, Ghani AC, Drakeley CJ. Factors determining  
493 the occurrence of submicroscopic malaria infections and their relevance for control.  
494 *Nature Communications*. 2012 Dec 4;3(1):1–9.
- 495 4. Tadesse FG, Slater HC, Chali W, Teelen K, Lanke K, Belachew M, Menberu T, Shumie G,  
496 Shitaye G, Okell LC, Graumans W, van Gemert G-J, Kedir S, Tesfaye A, Belachew F, Abebe  
497 W, Mamo H, Sauerwein R, Balcha T, Aseffa A, Yewhalaw D, Gadisa E, Drakeley C, Bousema  
498 T. The Relative Contribution of Symptomatic and Asymptomatic Plasmodium vivax and  
499 Plasmodium falciparum Infections to the Infectious Reservoir in a Low-Endemic Setting in  
500 Ethiopia. *Clin Infect Dis*. 2018 01;66(12):1883–1891. PMID: 29304258
- 501 5. Slater HC, Ross A, Felger I, Hofmann NE, Robinson L, Cook J, Gonçalves BP, Björkman A,  
502 Ouedraogo AL, Morris U, Msellem M, Koepfli C, Mueller I, Tadesse F, Gadisa E, Das S,  
503 Domingo G, Kapulu M, Midega J, Owusu-Agyei S, Nabet C, Piarroux R, Doumbo O, Doumbo  
504 SN, Koram K, Lucchi N, Udhayakumar V, Mosha J, Tiono A, Chandramohan D, Gosling R,  
505 Mwingira F, Sauerwein R, Riley EM, White NJ, Nosten F, Imwong M, Bousema T, Drakeley  
506 C, Okell LC. The temporal dynamics and infectiousness of subpatent Plasmodium  
507 falciparum infections in relation to parasite density. *Nature Communications*. 2019 Mar  
508 29;10(1):1433.
- 509 6. Zuk M, McKean KA. Sex differences in parasite infections: Patterns and processes.  
510 *International Journal for Parasitology*. 1996 Oct 1;26(10):1009–1024.
- 511 7. Klein SL. Hormonal and immunological mechanisms mediating sex differences in parasite  
512 infection. *Parasite Immunology*. 2004;26(6–7):247–264.
- 513 8. Roberts CW, Walker W, Alexander J. Sex-Associated Hormones and Immunity to Protozoan  
514 Parasites. *Clin Microbiol Rev*. 2001 Jul 1;14(3):476–488.
- 515 9. Desai M, Kuile FO ter, Nosten F, McGready R, Asamo K, Brabin B, Newman RD.  
516 Epidemiology and burden of malaria in pregnancy. *The Lancet Infectious Diseases*. 2007  
517 Feb 1;7(2):93–104. PMID: 17251080
- 518 10. Molineaux L, Gramiccia G, Organization WH. The Garki project: research on the  
519 epidemiology and control of malaria in the Sudan savanna of West Africa [Internet]. World

- 520 Health Organization; 1980 [cited 2020 Feb 18]. Available from:  
521 <https://apps.who.int/iris/handle/10665/40316>
- 522 11. Pathak S, Rege M, Gogtay NJ, Aigal U, Sharma SK, Valecha N, Bhanot G, Kshirsagar NA,  
523 Sharma S. Age-Dependent Sex Bias in Clinical Malarial Disease in Hypoendemic Regions.  
524 PLoS One [Internet]. 2012 Apr 25 [cited 2020 Feb 18];7(4). Available from:  
525 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338423/> PMID: PMC3338423
- 526 12. Landgraf B, Kollaritsch H, Wiedermann G, Wernsdorfer WH. Parasite density of  
527 Plasmodium falciparum malaria in Ghanaian schoolchildren: evidence for influence of sex  
528 hormones? Transactions of the Royal Society of Tropical Medicine and Hygiene. 1994  
529 Jan;88(1):73–74.
- 530 13. Camargo LMA, Colletto GMDD, Ferreira MU, Gurgel SDM, Escobar AL, Marques A, Krieger  
531 H, Camargo EP, Silva LHPD. Hypoendemic Malaria in Rondonia (Brazil, Western Amazon  
532 Region): Seasonal Variation and Risk Groups in an Urban Locality. The American Journal of  
533 Tropical Medicine and Hygiene. 1996 Jul 1;55(1):32–38.
- 534 14. Abdalla SI, Malik EM, Ali KM. The burden of malaria in Sudan: incidence, mortality and  
535 disability – adjusted life – years. Malar J. 2007 Jul 28;6:97. PMID: PMC1995207
- 536 15. Hounbedji CA, N’Dri PB, Hürlimann E, Yapi RB, Silué KD, Soro G, Koudou BG, Acka CA, Assi  
537 S-B, Vounatsou P, N’Goran EK, Fantodji A, Utzinger J, Raso G. Disparities of Plasmodium  
538 falciparum infection, malaria-related morbidity and access to malaria prevention and  
539 treatment among school-aged children: a national cross-sectional survey in Côte d’Ivoire.  
540 Malar J [Internet]. 2015 Jan 5 [cited 2020 Aug 5];14. Available from:  
541 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326184/> PMID: PMC4326184
- 542 16. Mulu A, Legesse M, Erko B, Belyhun Y, Nugussie D, Shimelis T, Kassu A, Elias D, Moges B.  
543 Epidemiological and clinical correlates of malaria-helminth co-infections in southern  
544 Ethiopia. Malar J. 2013 Jul 3;12:227. PMID: PMC3706225
- 545 17. Moon JJ, Cho S-Y. Incidence patterns of vivax malaria in civilians residing in a high-risk  
546 county of Kyonggi-do (Province), Republic of Korea. Korean J Parasitol. 2001  
547 Dec;39(4):293–299. PMID: PMC2721214
- 548 18. Finda MF, Moshi IR, Monroe A, Limwagu AJ, Nyoni AP, Swai JK, Ngowo HS, Minja EG, Toe  
549 LP, Kaindoa EW, Coetzee M, Manderson L, Okumu FO. Linking human behaviours and  
550 malaria vector biting risk in south-eastern Tanzania. PLoS One [Internet]. 2019 Jun 3 [cited  
551 2020 Apr 8];14(6). Available from:  
552 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546273/> PMID: PMC6546273
- 553 19. Nhamoyebonde S, Leslie A. Biological Differences Between the Sexes and Susceptibility to  
554 Tuberculosis. J Infect Dis. 2014 Jul 15;209(suppl\_3):S100–S106.



- 555 20. Bernin H, Lotter H. Sex Bias in the Outcome of Human Tropical Infectious Diseases:  
556 Influence of Steroid Hormones. *J Infect Dis*. 2014 Jul 15;209(suppl\_3):S107–S113.
- 557 21. Fischer J, Jung N, Robinson N, Lehmann C. Sex differences in immune responses to  
558 infectious diseases. *Infection*. 2015 Aug 1;43(4):399–403.
- 559 22. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. *Nat*  
560 *Rev Immunol*. 2008 Sep;8(9):737–744.
- 561 23. Klein SL, Shann F, Moss WJ, Benn CS, Aaby P. RTS,S Malaria Vaccine and Increased  
562 Mortality in Girls. *mBio* [Internet]. 2016 Apr 26 [cited 2020 Feb 18];7(2). Available from:  
563 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850267/> PMID: PMC4850267
- 564 24. Delić D, Ellinger-Ziegelbauer H, Vohr HW, Dkhil M, Al-Quraishy S, Wunderlich F.  
565 Testosterone response of hepatic gene expression in female mice having acquired  
566 testosterone-unresponsive immunity to *Plasmodium chabaudi* malaria. *Steroids*. 2011  
567 Oct;76(10–11):1204–1212. PMID: 21669218
- 568 25. Wunderlich, F, Marinovski P, Peter W, Benten M, Schmitt-Wrede, H-P, Mossman H.  
569 Testosterone and Other Gonadal Factor(s) Restrict the Efficacy of Genes Controlling  
570 Resistance to *Plasmodium Chabaudi* Malaria [Internet]. *Parasite immunology*. 1991.  
571 *Parasite Immunology*, 13: 357-367. doi:10.1111/j.1365-3024.1991.tb00289.x
- 572 26. Felger I, Maire M, Bretscher MT, Falk N, Tiaden A, Sama W, Beck H-P, Owusu-Agyei S,  
573 Smith TA. The Dynamics of Natural *Plasmodium falciparum* Infections. *PLOS ONE*. 2012  
574 Sep 18;7(9):e45542.
- 575 27. Smith T, Felger I, Fraser-Hurt N, Beck H-P. 10. Effect of insecticide-treated bed nets on the  
576 dynamics of multiple *Plasmodium falciparum* infections. *Transactions of the Royal Society*  
577 *of Tropical Medicine and Hygiene*. 1999 Feb 1;93:53–57.
- 578 28. Nankabirwa JI, Briggs J, Rek J, Arinaitwe E, Nayebare P, Katrak S, Staedke SG, Rosenthal PJ,  
579 Rodriguez-Barraquer I, Kanya MR, Dorsey G, Greenhouse B. Persistent Parasitemia  
580 Despite Dramatic Reduction in Malaria Incidence After 3 Rounds of Indoor Residual  
581 Spraying in Tororo, Uganda. *J Infect Dis*. 2019 Mar 15;219(7):1104–1111. PMID:  
582 PMC6420168
- 583 29. Nankabirwa JI, Arinaitwe E, Rek J, Kilama M, Kizza T, Staedke SG, Rosenthal PJ, Rodriguez-  
584 Barraquer I, Briggs J, Greenhouse B, Bousema T, Drakeley C, Roos DS, Tomko SS, Smith DL,  
585 Kanya MR, Dorsey G. Malaria Transmission, Infection, and Disease following Sustained  
586 Indoor Residual Spraying of Insecticide in Tororo, Uganda. *The American Journal of*  
587 *Tropical Medicine and Hygiene*; 2020 Jul 20;tpmd200250.
- 588 30. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive  
589 detection of *Plasmodium falciparum* by amplification of multi-copy subtelomeric targets.  
590 *PLoS Med*. 2015 Mar;12(3):e1001788. PMID: PMC4348198

- 591 31. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown  
592 KN. High sensitivity of detection of human malaria parasites by the use of nested  
593 polymerase chain reaction. *Mol Biochem Parasitol.* 1993 Oct;61(2):315–320. PMID:  
594 8264734
- 595 32. Miller RH, Hathaway NJ, Kharabora O, Mwandagalirwa K, Tshetu A, Meshnick SR, Taylor  
596 SM, Juliano JJ, Stewart VA, Bailey JA. A deep sequencing approach to estimate *Plasmodium*  
597 *falciparum* complexity of infection (COI) and explore apical membrane antigen 1 diversity.  
598 *Malar J.* 2017 Dec 16;16(1):490. PMCID: PMC5732508
- 599 33. Hathaway NJ, Parobek CM, Juliano JJ, Bailey JA. SeekDeep: single-base resolution de novo  
600 clustering for amplicon deep sequencing. *Nucleic Acids Res.* 2018 Feb 28;46(4):e21–e21.
- 601 34. Lerch A, Koepfli C, Hofmann NE, Kattenberg JH, Rosanas-Urgell A, Betuela I, Mueller I,  
602 Felger I. Longitudinal tracking and quantification of individual *Plasmodium falciparum*  
603 clones in complex infections. *Sci Rep [Internet].* 2019 Mar 4 [cited 2020 Feb 18];9.  
604 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399284/> PMCID:  
605 PMC6399284
- 606 35. Koepfli C, Mueller I. Malaria Epidemiology at the Clone Level. *Trends Parasitol.* 2017  
607 Dec;33(12):974–985. PMCID: PMC5777529
- 608 36. Nguyen T-N, von Seidlein L, Nguyen T-V, Truong P-N, Hung SD, Pham H-T, Nguyen T-U, Le  
609 TD, Dao VH, Mukaka M, Day NP, White NJ, Dondorp AM, Thwaites GE, Hien TT. The  
610 persistence and oscillations of submicroscopic *Plasmodium falciparum* and *Plasmodium*  
611 *vivax* infections over time in Vietnam: an open cohort study. *Lancet Infect Dis.* 2018  
612 May;18(5):565–572. PMCID: PMC5910058
- 613 37. Koepfli C, Schoepflin S, Bretscher M, Lin E, Kiniboro B, Zimmerman PA, Siba P, Smith TA,  
614 Mueller I, Felger I. How much remains undetected? Probability of molecular detection of  
615 human Plasmodia in the field. *PLoS ONE.* 2011 Apr 28;6(4):e19010. PMCID: PMC3084249
- 616 38. Ross A, Koepfli C, Li X, Schoepflin S, Siba P, Mueller I, Felger I, Smith T. Estimating the  
617 numbers of malaria infections in blood samples using high-resolution genotyping data.  
618 *PLoS ONE.* 2012;7(8):e42496. PMCID: PMC3430681
- 619 39. Lerch A, Koepfli C, Hofmann NE, Messerli C, Wilcox S, Kattenberg JH, Betuela I, O'Connor L,  
620 Mueller I, Felger I. Development of amplicon deep sequencing markers and data analysis  
621 pipeline for genotyping multi-clonal malaria infections. *BMC Genomics.* 2017 Nov  
622 13;18(1):864.
- 623 40. R Core Team. R: A language and environment for statistical computing. [Internet]. R  
624 Foundation for Statistical Computing, Vienna, Austria.; 2019. Available from: URL  
625 <https://www.R-project.org/>.

- 626 41. Python Language Reference, version 3.7.4. [Internet]. Python Software Foundation.;  
627 Available from: Available at <http://www.python.org>
- 628 42. Rondeau V, Gonzalez JR. frailtypack: A computer program for the analysis of correlated  
629 failure time data using penalized likelihood estimation. *Computer Methods and Programs*  
630 *in Biomedicine*. 2005 Nov 1;80(2):154–164.
- 631 43. Rondeau V, Marzroui Y, Gonzalez JR. frailtypack: An R Package for the Analysis of  
632 Correlated Survival Data with Frailty Models Using Penalized Likelihood Estimation or  
633 Parametrical Estimation. *Journal of Statistical Software*. 2012 Apr 17;47(1):1–28.
- 634 44. Briggs J. 2020. Sex\_based\_differences. Github.  
635 [https://github.com/EPPIcenter/sex\\_based\\_differences.git](https://github.com/EPPIcenter/sex_based_differences.git). cf6c325.
- 636